Advaxis Passion and Values

Our passion is to improve the lives of cancer patients and their loved ones.

We distinguish ourselves through Integrity, Accountability and Collaboration

LEADERSHIP

Advaxis has assembled a world class management team with extensive expertise and a successful track record in drug development and commercialization of cancer immunotherapies.

Kenneth A. Berlin

PRESIDENT AND CHIEF EXECUTIVE OFFICER

Mr. Kenneth A. Berlin, President and CEO of Advaxis, joined the company from Rosetta Genomics, where since 2009 he was President and Chief Executive Officer. During his tenure at Rosetta, Mr. Berlin spearheaded the effort of repositioning the company for commercial success with various microRNA-based oncology diagnostic products and raised nearly $100 million in capital to fund these efforts.

Prior to Rosetta Genomics, Mr. Berlin was Worldwide General Manager at cellular and molecular cancer diagnostics developer Veridex, LLC, a Johnson & Johnson company. At Veridex he grew the organization to over 100 employees, launched three cancer diagnostic products, led the acquisition of its cellular diagnostics partner, and delivered significant growth in sales as Veridex transitioned from an R&D entity to a commercial provider of oncology diagnostic products and services. During Mr. Berlin’s tenure, Veridex received numerous awards including recognition from the Cleveland Clinic and Prix Galien for the use of its innovative CellSearch® technology in the fight against cancer.

Mr. Berlin joined Johnson & Johnson in 1994 and served as corporate counsel for six years. He led and participated on the legal team that oversaw several mergers, acquisitions, divestitures and commercial transactions. He then held positions of increasing responsibility within Johnson & Johnson and a number of its subsidiary companies. From 2001 until 2004 he served as Vice President, Licensing and New Business Development in the pharmaceuticals group, and from 2004 until 2007 served as Worldwide Vice President, Franchise Development, Ortho-Clinical Diagnostics. He has been responsible for numerous licensing and/or research collaboration deals in oncology, metabolic disease, cardiovascular disease, CNS and women’s health, including the ex-U.S. license to Millennium Pharmaceutical’s VELCADE, a first-in-class, oncology therapeutic with peak reported sales outside the U.S. of approximately $1.8 billion.  Mr. Berlin holds an A.B. degree from Princeton University and a J.D. from the University of California Los Angeles School of Law.

Andres A. Gutierrez, M.D., Ph.D.

EXECUTIVE VICE PRESIDENT AND CHIEF MEDICAL OFFICER

Dr. Andres Gutierrez will be responsible for all global clinical development and regulatory initiatives for Advaxis’ novel Lm-based antigen delivery platform. He has more than 25 years of experience in clinical oncology and drug development and joins Advaxis from Oncolytics Biotech, Inc., where he served as Chief Medical Officer. Prior to Oncolytics, Dr. Gutierrez was Chief Medical Officer at SELLAS Life Sciences Group and was Medical Director, Early Development Immuno-Oncology at Bristol-Myers Squibb, where he oversaw the development of translational and clinical development of immuno-oncology programs in solid tumors and hematological malignancies. Earlier, Dr. Gutierrez was Medical Director for several biotechnology companies including Sunesis Pharmaceuticals, BioMarin Pharmaceutical, Proteolix and Oculus Innovative Sciences, leading key programs with talazoparib and carfilzomib, among others . Prior to Oculus, he served as Director of the Gene & Cell Therapy Unit at the National Institutes of Health in Mexico City and as a consultant physician at the Hospital Angeles del Pedregal.

Dr. Gutierrez received his M.D. and a Ph.D. in biomedical science from the National University of Mexico, with board certification in internal medicine and a fellowship in clinical oncology at the Hammersmith Hospital in London. He has presented clinical data at more than 85 scientific and medical meetings, has written numerous peer-reviewed articles, is a contributing author on nine medical textbooks and is named on 20 patents relating to drug development.

Molly Henderson

EXECUTIVE VICE PRESIDENT AND CHIEF FINANCIAL OFFICER

Ms. Henderson joins Advaxis from Cedar Cliff, LLC, where she served as a financial and business consultant to high-growth entrepreneurial companies. Previously she was Chief Financial Officer at Iovance Biotherapeutics, Inc. (formerly Lion Biotechnologies, Inc.) (Nasdaq: IOVA), an immuno-oncology company where she was responsible for all financial, SEC reporting, legal, governance, human resources and IT-related functions, and raised $100 million in equity capital. In her over twenty years of financial experience, Ms. Henderson brings to Advaxis a demonstrated set of skills that includes operational efficiency, fund raising, M&A evaluation, investor relations, accounting and financial controls.

Prior to Iovance, for more than a decade Ms. Henderson was Chief Business & Financial Officer, Senior Vice President of VirtualScopics, Inc. (formerly Nasdaq: VSCP) during a period when the company evolved from an early stage company to a publicly-traded profitable business serving the biotechnology and pharmaceutical industries. Earlier in her career Ms. Henderson was Corporate Controller at Ultralife Corporation and an expert advisor to entrepreneurs in Switzerland. She began her career as an audit manager at PricewaterhouseCoopers.

Ms. Henderson holds an MBA and a BS in Accounting from the University at Buffalo. She is a licensed CPA (inactive) in the State of New York.

Robert G. Petit, Ph.D.

Chair of Scientific Advisory Board

Dr. Robert Petit has 23 years of experience as an immunologist in all medical and scientific aspects of pharmaceutical development. He has led programs in discovery, translational development and intellectual property development and has designed and conducted U.S. and international clinical evaluation programs from Phase 1 to 4. Dr. Petit joined Advaxis from Bristol-Myers Squibb where he was the U.S. Medical Strategy Lead for the ipilimumab program, Director of Medical Strategy for New Oncology Products, and Director of Global Clinical Research. Prior to joining Bristol-Myers Squibb, Robert served as Vice President of Clinical Development at MGI Pharma and also at Aesgen Inc. His scientific focus has been to develop immunologic based therapies with a particular emphasis on immunologic oncology treatment. Robert has had significant FDA experience and has contributed to five NDA/BLA filings. Dr. Petit has a doctorate from the Ohio State University College of Medicine and a Bachelor of Science from Indiana State University.

BOARD OF DIRECTORS

David Sidransky, MD

CHAIRMAN OF THE BOARD

Dr. Sidransky is a renowned oncologist and research scientist named and profiled by TIME magazine in 2001 as one of the top physicians and scientists in America, recognized for his work with early detection of cancer. Since 1994, Dr. Sidransky has been the Director of the Head and Neck Cancer Research Division and Professor of Oncology, Otolaryngology, Genetics and Pathology at Johns Hopkins University School of Medicine. He has served as Chairman of the Board of Directors of Champions Oncology since October 2007 and was, until the merger with Eli Lilly, a Director and Vice-Chairman of ImClone Systems, Inc. He is the Chairman of Tamir Biotechnology and serves on the Board of Directors of Rosetta Genomics, Immune Pharmaceuticals and Celsus. He is serving and has served on scientific advisory boards of MedImmune, Roche, Amgen and Veridex, LLC (a Johnson & Johnson diagnostic company), among others. Dr. Sidransky served as Director (2005-2008) of the American Association for Cancer Research (AACR).

James Patton, MD, MBA

VICE CHAIRMAN OF THE BOARD

Dr. Patton currently serves as the Vice Chairman of the Board of Directors and has served as a member of the Board of Directors since February 2002. Furthermore, Dr. Patton was the Chairman of the Board of Directors from November 2004 until December 2005 and was the Chief Executive Officer from February 2002 to November 2002. Since February 1999, Dr. Patton has been the Vice President of Millennium Oncology Management, Inc., which provides management services for radiation oncology care to four sites. Dr. Patton was a trustee of Dundee Wealth U.S., a mutual fund family, from October 2006 through September 2014. He is a founder and has been chairman of VAL Health, LLC, a health care consultancy, from 2011 to the present. In addition, he was President of Comprehensive Oncology Care, LLC since 1999, a company that owned and operated a cancer treatment facility in Exton, Pennsylvania until its sale in 2008. From February 1999 to September 2003, Dr. Patton also served as a consultant to LibertyView Equity Partners SBIC, LP, a venture capital fund based in Jersey City, New Jersey. From July 2000 to December 2002, Dr. Patton served as a director of Pinpoint Data Corp. From February 2000 to November 2000, Dr. Patton served as a director of Healthware Solutions. From June 2000 to June 2003, Dr. Patton served as a director of LifeStar Response. He earned his Bachelor of Science from the University of Michigan, his Medical Doctorate from Medical College of Pennsylvania, and his Master of Business Administration from Penn’s Wharton School. Dr. Patton was also a Robert Wood Johnson Foundation Clinical Scholar. He has published papers regarding scientific research in human genetics, diagnostic test performance and medical economic analysis. Dr. Patton’s experience as a trustee and consultant to funds that invest in life science companies provides him with the perspective from which the company benefits. Additionally, Dr. Patton’s medical experience and service as a principal and director of other life science companies make Dr. Patton particularly qualified to serve as director and non-executive chairman.

Samir N. Khleif

M.D. Director

Dr. Khleif currently serves as the Director of the State of Georgia Cancer Center, Georgia Regents University Cancer Center and the Cancer Service Line. Dr. Khleif was formerly Chief of the Cancer Vaccine Section at the National Cancer Institute (NCI), and also served as a Special Assistant to the Commissioner of the Food and Drug Administration (FDA) leading the Critical Path Initiative for oncology. Dr. Khleif is a Georgia Research Alliance Distinguished Cancer Scientist and Clinician and holds a professorship in Medicine, Biochemistry and Molecular Biology, and Graduate Studies at Georgia Regents University. Dr. Khleif’s research program at Georgia Regents University Cancer Center focuses on understanding the mechanisms of cancer-induced immune suppression, and utilizing this knowledge for the development of novel immune therapeutics and vaccines against cancer. His research group designed and performed some of the first cancer vaccine clinical trials targeting specific genetic changes in cancer cells. He led many national efforts and committees on the development of biomarkers and integration of biomarkers in clinical trials, including the AACR-NCI-FDA Cancer Biomarker Collaborative and the ASCO Alternative Clinical Trial Design. Dr. Khleif is the author of many book chapters and scientific articles on tumor immunology and biomarkers process development, and he is the editor for two textbooks on cancer therapeutics, tumor immunology and cancer vaccines. Dr. Khleif was inducted into the American Society for Clinical Investigation, received the National Cancer Institute’s Director Golden Star Award, the National Institutes of Health Award for Merit, the Commendation Medal of the U.S. Public Health Service and he was recently appointed to the Institute of Medicine National Cancer Policy Forum.

Richard Berman, MBA

DIRECTOR

Mr. Berman has served as a member of the Board of Directors since September 1, 2005. Richard Berman’s business career spans over 35 years of venture capital, senior management and merger and acquisitions experience. In the past five years, Mr. Berman has served as a director and/or officer of over a dozen public and private companies. From 2006 to 2011, he was Chairman of National Investment Managers, a company with $12 billion in pension administration assets. In 2012, he became vice chairman of Energy Smart Resources, Inc. From 1998 to 2012, Mr. Berman served as a Director of Easy Link Int’l. Mr. Berman is currently a director of three public companies: Advaxis, Inc., Neostem, Inc. (since 2005) and Lustros, Inc. (since 2012). From 1998 to 2000, he was employed by Internet Commerce Corporation (now Easylink Services) as Chairman and CEO. Previously, Mr. Berman worked at Goldman Sachs; was Senior Vice President of Bankers Trust Company, where he started the M&A and Leveraged Buyout Departments; created the largest battery company in the world in the 1980s by merging Prestolite, General Battery and Exide to form Exide Technologies (XIDE); helped to create what is now Soho (NYC) by developing five buildings; and advised on over $4 billion of M&A transactions (completed over 300 deals). He is a past Director of the Stern School of Business of NYU where he obtained his Bachelor of Science and Master of Business Administration. He also has U.S. and foreign law degrees from Boston College and The Hague Academy of International Law, respectively. Mr. Berman’s extensive knowledge of the industry, his role in the governance of publicly held companies and his directorships in other life science companies qualify him to serve as director.

Roni A. Appel, MBA

DIRECTOR

Mr. Appel has served as a member of the Board of Directors since November 2004. He was Advaxis’ President and Chief Executive Officer from January 2006 and Secretary and Chief Financial Officer from November 2004, until he resigned as Chief Financial Officer on September 7, 2006 and as President, Chief Executive Officer and Secretary on December 15, 2006. From December 15, 2006 to December 2007, Mr. Appel served as a consultant to Advaxis. Mr. Appel currently is a self-employed consultant. Previously, he served as Chief Executive Officer of Anima Cell Metrology Ltd., from 2008 through January 31, 2013. From 1999 to 2004, he was a partner and Managing Director of LV Equity Partners (formerly LibertyView Equity Partners). From 1998 until 1999, he was a Director of Business Development at Americana Financial Services, Inc. From 1994 to 1998, he was an attorney and completed his Master of Business Administration at Columbia University. Mr. Appel’s longstanding service with Advaxis and his entrepreneurial investment career in early stage biotech businesses qualify him to serve as director.

Kenneth A. Berlin

DIRECTOR

Mr. Kenneth A. Berlin, President and CEO of Advaxis, joined the company from Rosetta Genomics, where since 2009 he was President and Chief Executive Officer. During his tenure at Rosetta, Mr. Berlin spearheaded the effort of repositioning the company for commercial success with various microRNA-based oncology diagnostic products and raised nearly $100 million in capital to fund these efforts.

Prior to Rosetta Genomics, Mr. Berlin was Worldwide General Manager at cellular and molecular cancer diagnostics developer Veridex, LLC, a Johnson & Johnson company. At Veridex he grew the organization to over 100 employees, launched three cancer diagnostic products, led the acquisition of its cellular diagnostics partner, and delivered significant growth in sales as Veridex transitioned from an R&D entity to a commercial provider of oncology diagnostic products and services. During Mr. Berlin’s tenure, Veridex received numerous awards including recognition from the Cleveland Clinic and Prix Galien for the use of its innovative CellSearch® technology in the fight against cancer.

Mr. Berlin joined Johnson & Johnson in 1994 and served as corporate counsel for six years. He led and participated on the legal team that oversaw several mergers, acquisitions, divestitures and commercial transactions. He then held positions of increasing responsibility within Johnson & Johnson and a number of its subsidiary companies. From 2001 until 2004 he served as Vice President, Licensing and New Business Development in the pharmaceuticals group, and from 2004 until 2007 served as Worldwide Vice President, Franchise Development, Ortho-Clinical Diagnostics. He has been responsible for numerous licensing and/or research collaboration deals in oncology, metabolic disease, cardiovascular disease, CNS and women’s health, including the ex-U.S. license to Millennium Pharmaceutical’s VELCADE, a first-in-class, oncology therapeutic with peak reported sales outside the U.S. of approximately $1.8 billion.  Mr. Berlin holds an A.B. degree from Princeton University and a J.D. from the University of California Los Angeles School of Law.

SCIENTIFIC ADVISORY BOARD

Dr. Robert Petit

PH.D.

Dr. Robert Petit has 23 years of experience as an immunologist in all medical and scientific aspects of pharmaceutical development. He has led programs in discovery, translational development and intellectual property development and has designed and conducted U.S. and international clinical evaluation programs from Phase 1 to 4. Dr. Petit joined Advaxis from Bristol-Myers Squibb where he was the U.S. Medical Strategy Lead for the ipilimumab program, Director of Medical Strategy for New Oncology Products, and Director of Global Clinical Research. Prior to joining Bristol-Myers Squibb, Robert served as Vice President of Clinical Development at MGI Pharma and also at Aesgen Inc. His scientific focus has been to develop immunologic based therapies with a particular emphasis on immunologic oncology treatment. Robert has had significant FDA experience and has contributed to five NDA/BLA filings. Dr. Petit has a doctorate from the Ohio State University College of Medicine and a Bachelor of Science from Indiana State University.

Antoni Ribas

MD, PHD

Dr. Ribas is a professor of medicine, professor of surgery, and professor of molecular and medical pharmacology at the University of California Los Angeles (UCLA). He is also director of the Tumor Immunology Program at the UCLA Jonsson Comprehensive Cancer Center (JCCC). Dr. Ribas conducts laboratory and clinical research in malignant melanoma, focusing on gene engineered adoptive cell transfer (ACT) therapies, anti-CTLA4 antibodies, anti-PD-1 antibodies, BRAF and MEK inhibitors and nanoparticle-siRNA.

Jedd Wolchok

MD, PHD

Dr. Wolchok is chief of the Melanoma and Immunotherapeutics service and is the Lloyd J. Old and Daniel K. Ludwig Chair in Clinical Investigation at Memorial Sloan Kettering Cancer Center. He is a specialist in melanoma with a clinical expertise in immunotherapy and cancer vaccines. Dr. Wolchok’s research focuses on the development of innovative ways to use the immune system to treat cancer.

Nancy Freitag

MD, PHD

Dr. Freitag is a professor in the Microbiology and Immunology Department and the Associate Director of the Medical Scientist Training Program at the University of Illinois at Chicago. Her research focuses on understanding how pathogens, including Listeria monocytogenes, come to invade and live within human and animal cells, and discovering the mechanisms used by mammalian cells to fight off pathogenic intruders.

Marc Lecuit

MD, PHD

Dr. Lecuit is a microbiologist and infectious diseases physician. He is the director of the Biology Infection Unit at Institut Pasteur and Inserm. He is a professor at the Paris Descartes University and deputy head of the Department of Infectious Diseases and Tropical Medicine at the Necker-Enfants Malades University Hospital. Listeria microbiology and listeriosis pathophysiology are a major focus of his research.

WORK WITH US

Join the Advaxis team in making a difference in treating cancer.

This page is being updated.

The Advaxis Vision

Advaxis was founded on the vision that no one should suffer from the burdens of cancer. Our goal is to develop cancer immunotherapies that teach the body to recognize tumors as a threat and do so in a way that minimizes side effects associated with traditional chemotherapy and radiation.

STAY TUNED

Mailing List

Sign up for email alerts for Press Releases and Advaxis breaking news.

Click here to sign up for alerts

SOCIAL

Follow Us

Stay up to date on the latest events, news, and happenings on Advaxis and Immunotherapy.